Mr. Read is an experienced chairman and director in public, private and government organisations. Through his extensive career in venture capital, private equity and commercialisation he has gained a depth of experience in the formation and growth of emerging companies with an emphasis on commercial entities that provide broad societal benefits. He is currently the Chairman of Pro-Pac Packing Limited (ASX:PPG), The Environmental Group Limited (ASX:EGL) and a Director of CVC Limited (ASX:CVC), CVC Private Equity Limited, CVC Sustainable Investments Limited and the Australian Institute of Commercialisation.

Dr. Roskrow is a haematologist and oncologist trained at the University of London. She has held many high level clinical and research positions, most recently as a leader in translational research at the GSF -National Research Centre for Environment and Health in Munich, Germany. She has extensive experience related to the early and later-stage clinical development of novel anti-cancer compounds and has earned many awards and honours for her work. Complementing her clinical research experience, Dr. Roskrow has worked for several years in healthcare investment banking, most recently at Lazard Ltd. She participated in many public and private biotechnology and pharmaceutical merger and acquisition deals, company financings and product in/out-licensing deals. In addition, Dr Roskrow has an extensive network of relationships with executives and board members of pharmaceutical and biotechnology companies and leading clinical centres.

Dr. Robertson has more than 20 years' experience in drug discovery and product development with leading pharmaceutical companies. In his current role as Chief Executive Officer and Managing Director of Pharmaxis Ltd (ASX: PXS , NASDAQ: PXSL ), a position he has held since its founding in 1999, Dr. Robertson has been responsible for leading Pharmaxis Ltd through successful clinical trials, product development, regulatory approval and marketing of its products. Previously, Dr. Robertson spent 8 years with Wellcome plc in London and with Australian companies Faulding Ltd and Amrad Ltd. The co-inventor of 18 patents and author of more than 35 scientific papers, Dr. Robertson gained a PhD in synthetic organic chemistry from the University of Glasgow and has extensive practical understanding of both the clinical and management aspects of the pharmaceutical industry. He has been actively involved in the discovery, development and marketing of various compounds, including new treatments for migraine and cardiovascular disease. Dr. Robertson is also the inventor of the migraine therapeutic Zomig, which is marketed worldwide by AstraZeneca.

Mr. Stork is the Managing Director of F.J. Stork Holdings Ltd., the parent entity for PNK Holdings Ltd, an original investor in Acceptys, Inc. and Patrys. Mr. Stork was until 2004 Chairman of the Board for Dspfactory Ltd, a leading edge developer of digital signal processing (DSP) technology for various applications including hearing aids, headsets and personal digital audio players. Mr. Stork has also played key roles in the management team and the Board of Directors for Unitron Industries Ltd., a hearing aid manufacturing Company that was voted one of the 50 Best Managed Private Companies in Canada for 2000. Unitron was sold to Phonak Holdings AG, a publicly traded Swiss Company, in 2002.

Ms. Jones is Founder and Managing Partner of DNA Ink LLC, a life sciences business development and licensing firm in San Francisco, California. Prior to starting her own firm, Ms. Jones spent 20 years at Genentech. Most recently, she was the Head of Business Development responsible for identifying external opportunities that supported the company’s business objectives, and overseeing the negotiation of collaboration agreements to support strategic alliances. Ms. Jones joined Genentech in 1990 as a research associate where she conducted basic immunology research, contributing to the development of two drug candidates. After leaving pure research, Ms. Jones worked in the Product Development group where she managed several products at various stages of their life-cycles, including two very successful cancer products, Rituxan and Avastin. In 2001, Ms. Jones joined the Business Development group where she spent nine years overseeing Genentech’s licensing efforts in immunology, infectious diseases, neurobiology, ophthalmology, metabolism, cardiovascular diseases as well as technology licensing. During her tenure, the Genentech Business Development group was recognised in an IBM survey as the number one deal-making and sourcing group in industry. Ms. Jones has very extensive networks within the pharmaceutical and biotech companies and the venture capital community in North America.